Efficacy
Psoriasis
PSORIASIS
The primary end point was the proportion of patients achieving clinical response at week 16. Clinical response was defined as “slightly improved” in the overall improvement rating from baseline according to the JDA total score for patients with GPP and as at least “minimally improved” in the Clinical Global Impression‐Global Improvement Scale for patients with EP. Secondary end points included the proportion of patients achieving clinical response at week 52 and ≥ 90% improvement in the Psoriasis Area and Severity Index (PASI 90) at weeks 16 and 52. Other efficacy end points assessed through week 180 (the last follow‐up visit) included achievement of clinical responses, PASI 90, Dermatology Life Quality Index of 0 or 1 (no effect) (DLQI 0/1), and change from baseline in total JDA scores (0 [best] to 17 [worst]) for patients with GPP.